Table 8.
Risk factor | Ampicillin | Danofloxacin | Enrofloxacin | Florfenicol | Oxytetracycline | Tilmicosin | Tulathromycin | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value | |
Country | |||||||||||||||||||||
CA | 1 | 1 | – | 1 | 1 | – | 1 | 1 | – | 1 | 1 | – | 1 | 1 | – | 1 | 1 | – | 1 | 1 | – |
US | na | na | na | 0.003 | 0.0003–0.04 | <0.001 | 0.01 | 0.001–0.1 | <0.001 | 0.09 | 0.02–0.4 | 0.002 | na | na | na | na | na | na | 0.01 | 0.001–0.1 | <0.001 |
Monthly intervals | |||||||||||||||||||||
Aug–Nov | 1 | 1 | – | 1 | 1 | – | 1 | 1 | – | 1 | 1 | – | 1 | 1 | – | 1 | 1 | – | 1 | 1 | – |
Dec–Feb | 1.53 | 0.3–6.8 | 0.568 | na | na | na | 0.7 | 0.2–2.3 | 0.588 | 2.5 | 0.9–6.1 | 0.053 | na | na | na | na | na | na | 0.4 | 0.1–1.1 | 0.063 |
Mar–May | 0.13 | 0.02–0.9 | 0.037 | na | na | na | 0.1 | 0.04–0.4 | <0.001 | 0.3 | 0.1–0.9 | 0.026 | na | na | na | na | na | na | 1.3 | 0.5–3.2 | 0.647 |
CA, Canada; CI, confident interval; OR, odds ratio.
na, that variable was not significant at the p-value ≤ 0.1 level and was eliminated from the regression.
Bold p-values indicate statistically significant results at p ≤ 0.1.